title: Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
abstract: Despite the increasing use of peripheral blood progenitor cells (PBPC) instead of bone marrow (BM) for allogeneic hematopoietic stem cell transplantation (allo HSCT) from human leukocyte antigen (HLA)-matched unrelated donors in children, the relative benefits and risks of both stem cell sources in the pediatric setting remain largely unknown. Recently, the only larger study comparing the value of the 2 stem cell sources in a young patient group was confined to transplantation from HLA-identical sibling donors in older children and adolescents with acute leukemia. Based on the paucity of data in pediatric HLA-matched unrelated donor transplantation, we analyzed the outcome of 23 BM and 38 PBPC transplantations performed at our center. Neutrophil and platelet engraftment were achieved significantly faster in PBPC compared to BM recipients (18 versus 22 days and 26 versus 33 days; P < .001 and P = .03) whereas the risk for grade II-IV acute graft-versus-host disease (aGVHD) (62% versus 55%; P = .53) and chronic GVHD (cGVHD 65% versus 59%; P = .54) was comparable. As overall survival (OS; PBPC versus BM: 47.5% +/- 8.6% versus 51.8% +/- 10.5%; P = .88) and relapse-free survival (43.3% +/- 8.3% versus 51.8% +/- 10.5%; P = .60) are without detectable difference, PBPC and BM appear both as a valid stem cell source for HLA-matched unrelated donor transplantation in children with hematologic malignancies.
authors.affiliation: Clinic for Pediatric Oncology, Hematology and Clinical Immunology, University Clinic of Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany. meisel@med.uni-duesseldorf.de
authors.forename: Roland
authors.initials: R
authors.lastname: Meisel
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Laws
authors.forename: Stefan
authors.initials: S
authors.lastname: Balzer
authors.forename: Benedikt
authors.initials: B
authors.lastname: Bernbeck
authors.forename: Christof
authors.initials: C
authors.lastname: Kramm
authors.forename: Stefan
authors.initials: S
authors.lastname: Schönberger
authors.forename: Kumar
authors.initials: K
authors.lastname: Sinha
authors.forename: Anja
authors.initials: A
authors.lastname: Tröger
authors.forename: Monika
authors.initials: M
authors.lastname: Schmitz
authors.forename: Johannes
authors.initials: J
authors.lastname: Fischer
authors.forename: Ulrich
authors.initials: U
authors.lastname: Göbel
authors.forename: Jürgen
authors.initials: J
authors.lastname: Enczmann
authors.forename: Dagmar
authors.initials: D
authors.lastname: Dilloo
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000379:methods / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005858:Germany / Q000453:epidemiology; D006085:Graft Survival; D006086:Graft vs Host Disease; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006801:Humans; D007223:Infant; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods / Q000401:mortality; D012189:Retrospective Studies; D017741:Survivors; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000401:mortality